Clinical trial
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell…
NCT00110617 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00110617 |
|---|---|
| Title | Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients |
| Official title | A Randomized, Open-label, Multi-center, Phase II Study to Evaluate the Safety and Efficacy of Deferasirox (ICL670) 20 mg/kg/Day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients With Iron Overload From Repeated Blood Transfusions |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sickle Cell Disease, Iron Overload, Hemolytic Anemia |
| Intervention type | Drug |
| Interventions | Deferasirox (ICL670), Deferoxamine (DFO) |
| Enrollment | 212 |
| Start date | May 1, 2005 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | May 11, 2005 |
| Last update posted | May 26, 2011 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: